KFDA Communicates Potential Safety Risks with Atopic Dermatitis Treatments

Published: 2005-03-18 06:57:00

Updated: 2005-03-18 06:57:00

The Korea Food and Drug Administration (KFDA) made a communication on the potential safety risks that are associated with pimecrolimus and tacrolimus, both which are indicated for treatment of atopic dermatitis (AD), in its March 16th Dear Healthcare Professional Letter.

The letter advises not to prescribe or dispense the AD medications containing pimecrolimus and tacrolimus to the infants o...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.